• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Pharma

Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH)

byAdrian CheandUsamah Bhaidu
October 18, 2024
in Pharma
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn
  1. ALG-055009, a thyroid hormone receptor agonist, significantly reduced liver fat in patients with MASH after 12 weeks of treatment.
  2. ALG-055009 was well tolerated, with no serious adverse events

The Latest

The HERALD study is a randomized, double-blind, placebo-controlled phase 2a clinical trial conducted by Aligos Therapeutics. The trial evaluated the safety and efficacy of ALG-055009 over the course of 12 weeks in 102 patients with MASH. Subjects were randomized to receive either 0.3 mg, 0.5 mg, 0.7 mg or 0.9 mg of ALG-055009 or placebo. Results showed that doses of 0.5 mg to 0.9 mg had statistically significant reductions in liver fat at week 12. Additionally, as much as 70% of participants achieved greater than 30% relative reduction in liver fat compared to baseline. ALG-05509 was well tolerated with no serious adverse events. Patients receiving ALG-055009 had similar incidence of gastrointestinal disturbances compared to placebo.

Physicians Perspective

Poor diet and lack of exercise can lead to fatty deposits in the liver leading to a condition known as metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD is estimated to occur in approximately 30% of the worldwide population. MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH) when the body undergoes an inflammatory response to the fatty deposits. The prevalence of MASH in the United States is projected to increase from 16.5 million in 2015 to 27 million in 2030. MASH has a high risk of progressing into liver cirrhosis (extensive scarring and dysfunction of the liver) and even cancer. Treatment is largely focused on optimizing risk factors by lifestyle changes and strict management of diabetes, hypertension and high cholesterol. Through its potent mechanism of action, ALG-055009 demonstrates the ability to significantly reduce fatty accumulation in the liver, and potentially reduce progression to severe liver scarring.

Molecular Targets

ALG-055009 is a thyroid hormone receptor-beta (THR-β) agonist. THR-β is the main form of the thyroid hormone receptor expressed in the liver and plays an important role in the metabolism of lipids. THR-β agonists act on these receptors in the liver leading to increased cholesterol and fat metabolism, reducing overall fatty deposition in the liver, and preventing further fibrosis.

RELATED REPORTS

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

A healthy lifestyle may reduce risk of infection in patients with type 2 diabetes

Company History

Aligos Therapeutics is a biopharmaceutical headquartered in San Francisco that focuses on best-in class therapies for liver and viral diseases. Their mission is to improve patient outcomes by applying new research and development to develop novel therapeutics for MASH and viruses with high unmet medical needs such as hepatitis B and coronaviruses.

Further Reading: https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-announces-positive-topline-results-phase-2a

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: endocrinologyhepatologyliver diseasemetabolic diseasemetabolic dysfunction-associated steatotic liver disease
Previous Post

Perioperative pembrolizumab improves survival in resectable early-stage non-small cell lung cancer

Next Post

#VisualAbtract: Durvalumab After Chemoradiotherapy Increased Survival in Limited-Stage Small-Cell Lung Cancer

RelatedReports

A liver illustration with spilled sugar cubes and two drink cups, highlighting the link between sugary drinks and liver health.
Chronic Disease

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

October 7, 2026
Physical activity collage: a smiling middle-aged man in a track jacket beside a city bicycle and a teal resistance band
Chronic Disease

A healthy lifestyle may reduce risk of infection in patients with type 2 diabetes

September 2, 2026
Fatty liver disease may independently predict high-risk coronary disease
Cardiology

Weight loss is associated with improved vascular function in patients with metabolic dysfunction-associated steatotic liver disease

August 21, 2026
Exercise collage: a smiling older woman with silver hair beside a pair of hand weights, a jump rope and a folded towel
Chronic Disease

Resistance training is associated with lower risk of type 2 diabetes

July 2, 2026
Next Post
#VisualAbtract: Durvalumab After Chemoradiotherapy Increased Survival in Limited-Stage Small-Cell Lung Cancer

#VisualAbtract: Durvalumab After Chemoradiotherapy Increased Survival in Limited-Stage Small-Cell Lung Cancer

Mineralocorticoid receptor antagonists reduce hospitalizations in patients with heart failure with preserved or mildly reduced ejection fraction

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

2 Minute Medicine Rewind October 21, 2024

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
  • Bariatric surgery associated with lower obesity-related cancer incidence in Nordic cohort
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.